Washington State Sues J&J Over Opioid Crisis -- Update

Date : 01/02/2020 @ 10:32PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 149.93  1.56 (1.05%) @ 1:00AM
After Hours
Last Trade
Last $ 149.86 ▼ -0.07 (-0.05%)

Washington State Sues J&J Over Opioid Crisis -- Update

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more Johnson and Johnson Charts.
   By Maria Armental 

Washington State sued Johnson & Johnson, accusing the drugmaker of fueling the opioid crisis in that state.

In a complaint filed in King County Superior Court, Attorney General Bob Ferguson accused J&J of embarking "on a massive deceptive marketing campaign" to convince doctors and the public that the drugs were effective in treating chronic pain and had a low risk of addiction.

"Unlike tobacco or alcohol about which no medical claims were made, patients were told by health care providers that opioids are a powerful medicine, safe to use as prescribed, and effective to relieve chronic pain," the suit reads. "Against this message, the public had no defense."

A representative for J&J's Janssen Pharmaceuticals subsidiary defended the company's actions in marketing and promoting the prescription pain medications as appropriate and responsible.

"We believe litigation is not the answer to public health crises, and we continue to work with partners to help communities in need," the company said.

Washington State--which has filed similar claims against drugmaker Purdue Pharma LP and drug distributors McKesson Corp., Cardinal Health Inc., and AmerisourceBergen Corp.--referred to an Oklahoma ruling last year ordering J&J to pay $465 million to help address the damage caused by opioid addiction in that state. J&J has appealed.

The Oklahoma case was the first to go to trial out of thousands of similar cases brought by cities, counties and states that say drugmakers and distributors are responsible for fueling the opioid epidemic by marketing drugs too aggressively and not providing oversight of how many of their prescription drugs flooded into communities.

J&J has offered to pay $4 billion to resolve the entirety of the opioid litigation as part of settlement talks between several companies and some state attorneys general. That deal is still far from finalized, however, as states try to reach a consensus on the overall settlement amount.


--Sara Randazzo contributed to this story.


Write to Maria Armental at maria.armental@wsj.com


(END) Dow Jones Newswires

January 02, 2020 17:17 ET (22:17 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.